News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2016

Epigenomics receives FDA approval for Epi proColon®

First and only blood-based colorectal cancer screening test approved by the FDA Innovative, convenient and effective screening option for millions of eligible Americans Commercialization initiated with partner Polymedco Berlin (Germany) and Germantown, MD (U.S.A.), April 13, 2016 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that […]

Read more

Epigenomics enters strategic license and development agreement with BioChain on novel, blood-based lung cancer test

PDF 241 KB   BioChain to acquire exclusive development and commercial license for China Initiation of clinical study planned in 2016 with the goal of gaining China Food and Drug Administration (CFDA) approval by BioChain  Epigenomics to receive upfront, milestone and minimum annual payments as well as royalties on future revenues Berlin (Germany) and Germantown, […]

Read more

Epigenomics enters strategic license and development agreement with BioChain on novel, blood-based lung cancer test for China

PDF 202 KB   Berlin, Germany, March 30, 2016 – Epigenomics AG, Berlin, Germany, (Frankfurt Prime Standard: ECX; ISIN: DE000A11QW50) announces that it has entered a strategic license agreement with BioChain on the development and commercialization of a novel, blood-based lung cancer test for China. BioChain will initiate a clinical trial to validate the lung cancer […]

Read more

Epigenomics AG Reports Results for the Financial Year Ended December 31, 2015 and Provides Outlook for 2016

PDF 123 KB Product revenue growth of 88% year-on-year driven by successful start of commercialization of Epi proColon® in China FDA review for approval of Epi proColon® expected to be completed soon Outlook 2016: Strong revenue growth upon launch in the U.S.A. Berlin (Germany) and Germantown, MD (U.S.A.), March 18, 2016 – Epigenomics AG (Frankfurt […]

Read more

Epigenomics receives FDA notification about status of pending approval decision for Epi proColon®

Ad hoc Releases 2016 Pursuant to § 15 WpHG (German Securities Trading Act) PDF 153 KB   Epigenomics receives FDA notification about status of pending approval decision for Epi proColon® Berlin, Germany, January 8, 2016 – Epigenomics AG, Berlin, Germany, (Frankfurt Prime Standard: ECX; ISIN: DE000A11QW50) the German-American cancer molecular diagnostics company, today announced that […]

Read more